Anhui Anke Biotechnology Group Co Ltd
SZSE:300009
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
7.59
12.3
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| CN |
|
Anhui Anke Biotechnology Group Co Ltd
SZSE:300009
|
17.5B CNY |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
394.7B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.9B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
175B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
120.2B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.6B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
88.6B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
44.1B EUR |
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
47.5B USD |
Loading...
|
Market Distribution
| Min | -409 046.1% |
| 30th Percentile | -1.4% |
| Median | 4.2% |
| 70th Percentile | 10.3% |
| Max | 876.4% |
Other Profitability Ratios
Anhui Anke Biotechnology Group Co Ltd
Glance View
Anhui Anke Biotechnology Group Co., Ltd., nestled in the heart of China's Anhui Province, weaves a story that blends innovation with a commitment to health. Founded in 1986, Anke Biotechnology made its mark early by focusing on the development and manufacturing of biopharmaceutical products. The company's narrative is rooted in its pursuit of cutting-edge technology, specifically in the fields of genetic engineering, fermentation technology, and vaccine production. As China looks to bolster its biopharmaceutical sector, Anke stands out with its robust pipeline of recombinant protein drugs and vaccines that cater to widespread public health needs. By leveraging advanced bioengineering processes, the company aims to encapsulate scientific complexity into tangible, life-saving treatments. At the core of its operations is a diverse business model that spans research, development, production, and commercialization of healthcare products. Through strategic alliances and continuous investment in R&D, Anke Biotechnology sustains a competitive edge by bringing innovative therapies to market. Revenue flows from its flagship products like recombinant human growth hormones and interferons, which address critical healthcare demands not just within China, but internationally as well. Furthermore, the company astutely capitalizes on the rising healthcare needs of an aging population, along with the increasing importance of preventive medicine, reflected in its vaccine offerings. It’s this strategic acumen, blended with scientific prowess, that allows Anhui Anke Biotechnology to thrive in an industry characterized by rapid innovation and evolving challenges.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Anhui Anke Biotechnology Group Co Ltd is 28.4%, which is below its 3-year median of 32.1%.
Over the last 3 years, Anhui Anke Biotechnology Group Co Ltd’s Operating Margin has increased from 19.8% to 28.4%. During this period, it reached a low of 19.8% on Aug 30, 2022 and a high of 36.6% on Dec 31, 2022.